TLR7 agonist in combination with

We evaluated a novel approach combining the use of attenuated immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice. B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumoral injection of attenuated serovar Typhimu...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2018-06, Vol.10 (8), p.665-679
Main Authors: Vola, Magdalena, Mónaco, Amy, Bascuas, Thais, Rimsky, Geraldine, Agorio, Caroline Isabel, Chabalgoity, José Alejandro, Moreno, María
Format: Article
Language:English
Subjects:
experimental model
imiquimod
immunotherapy
melanoma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 679
container_issue 8
container_start_page 665
container_title Immunotherapy
container_volume 10
creator Vola, Magdalena
Mónaco, Amy
Bascuas, Thais
Rimsky, Geraldine
Agorio, Caroline Isabel
Chabalgoity, José Alejandro
Moreno, María
description We evaluated a novel approach combining the use of attenuated immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice. B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumoral injection of attenuated serovar Typhimurium LVR01. The combined therapy resulted in retarded tumor growth and prolonged survival. Combination treatment led to an enhancement in the expression of pro-inflammatory cytokines and chemokines in the tumor microenvironment, with a Th1-skewed profile, resulting in a broad antitumor response. The induced immunity was effective in controlling the occurrence of metastasis. LVR01 immunotherapy in combination with imiquimod is a novel approach that could be considered as an effective antimelanoma therapy.
doi_str_mv 10.2217/imt-2017-0188
format article
fullrecord <record><control><sourceid>futurescience</sourceid><recordid>TN_cdi_futurescience_futuremedicine_10_2217_imt_2017_0188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2217_imt_2017_0188</sourcerecordid><originalsourceid>FETCH-futurescience_futuremedicine_10_2217_imt_2017_01883</originalsourceid><addsrcrecordid>eNpjYBA1NNAzMjI018_MLdE1MjA01zUwtLBgYuA0NDc10DU3MbFggbONIzgYuIqLswwMzEzMzUw4GRRCfILMFRLT8_Myi0sUMvMUkvNzkzLzEksy8_MUyjNLMngYWNMSc4pTeaE0N4Olm2uIs4duWmlJaVFqcXJmal5yajyEl5uakpmcmZcab2gQD3JSPNBJ8SAnxYOcZEyJXgCoq0L7</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>TLR7 agonist in combination with</title><source>PubMed Central</source><creator>Vola, Magdalena ; Mónaco, Amy ; Bascuas, Thais ; Rimsky, Geraldine ; Agorio, Caroline Isabel ; Chabalgoity, José Alejandro ; Moreno, María</creator><creatorcontrib>Vola, Magdalena ; Mónaco, Amy ; Bascuas, Thais ; Rimsky, Geraldine ; Agorio, Caroline Isabel ; Chabalgoity, José Alejandro ; Moreno, María</creatorcontrib><description>We evaluated a novel approach combining the use of attenuated immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice. B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumoral injection of attenuated serovar Typhimurium LVR01. The combined therapy resulted in retarded tumor growth and prolonged survival. Combination treatment led to an enhancement in the expression of pro-inflammatory cytokines and chemokines in the tumor microenvironment, with a Th1-skewed profile, resulting in a broad antitumor response. The induced immunity was effective in controlling the occurrence of metastasis. LVR01 immunotherapy in combination with imiquimod is a novel approach that could be considered as an effective antimelanoma therapy.</description><identifier>ISSN: 1750-743X</identifier><identifier>EISSN: 1750-7448</identifier><identifier>DOI: 10.2217/imt-2017-0188</identifier><language>eng</language><publisher>Future Medicine Ltd</publisher><subject>experimental model ; imiquimod ; immunotherapy ; melanoma</subject><ispartof>Immunotherapy, 2018-06, Vol.10 (8), p.665-679</ispartof><rights>2018 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Vola, Magdalena</creatorcontrib><creatorcontrib>Mónaco, Amy</creatorcontrib><creatorcontrib>Bascuas, Thais</creatorcontrib><creatorcontrib>Rimsky, Geraldine</creatorcontrib><creatorcontrib>Agorio, Caroline Isabel</creatorcontrib><creatorcontrib>Chabalgoity, José Alejandro</creatorcontrib><creatorcontrib>Moreno, María</creatorcontrib><title>TLR7 agonist in combination with</title><title>Immunotherapy</title><description>We evaluated a novel approach combining the use of attenuated immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice. B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumoral injection of attenuated serovar Typhimurium LVR01. The combined therapy resulted in retarded tumor growth and prolonged survival. Combination treatment led to an enhancement in the expression of pro-inflammatory cytokines and chemokines in the tumor microenvironment, with a Th1-skewed profile, resulting in a broad antitumor response. The induced immunity was effective in controlling the occurrence of metastasis. LVR01 immunotherapy in combination with imiquimod is a novel approach that could be considered as an effective antimelanoma therapy.</description><subject>experimental model</subject><subject>imiquimod</subject><subject>immunotherapy</subject><subject>melanoma</subject><issn>1750-743X</issn><issn>1750-7448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNpjYBA1NNAzMjI018_MLdE1MjA01zUwtLBgYuA0NDc10DU3MbFggbONIzgYuIqLswwMzEzMzUw4GRRCfILMFRLT8_Myi0sUMvMUkvNzkzLzEksy8_MUyjNLMngYWNMSc4pTeaE0N4Olm2uIs4duWmlJaVFqcXJmal5yajyEl5uakpmcmZcab2gQD3JSPNBJ8SAnxYOcZEyJXgCoq0L7</recordid><startdate>20180601</startdate><startdate>20180301</startdate><enddate>20180601</enddate><enddate>20180301</enddate><creator>Vola, Magdalena</creator><creator>Mónaco, Amy</creator><creator>Bascuas, Thais</creator><creator>Rimsky, Geraldine</creator><creator>Agorio, Caroline Isabel</creator><creator>Chabalgoity, José Alejandro</creator><creator>Moreno, María</creator><general>Future Medicine Ltd</general><scope/></search><sort><creationdate>20180601</creationdate><title>TLR7 agonist in combination with</title><author>Vola, Magdalena ; Mónaco, Amy ; Bascuas, Thais ; Rimsky, Geraldine ; Agorio, Caroline Isabel ; Chabalgoity, José Alejandro ; Moreno, María</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-futurescience_futuremedicine_10_2217_imt_2017_01883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>experimental model</topic><topic>imiquimod</topic><topic>immunotherapy</topic><topic>melanoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vola, Magdalena</creatorcontrib><creatorcontrib>Mónaco, Amy</creatorcontrib><creatorcontrib>Bascuas, Thais</creatorcontrib><creatorcontrib>Rimsky, Geraldine</creatorcontrib><creatorcontrib>Agorio, Caroline Isabel</creatorcontrib><creatorcontrib>Chabalgoity, José Alejandro</creatorcontrib><creatorcontrib>Moreno, María</creatorcontrib><jtitle>Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vola, Magdalena</au><au>Mónaco, Amy</au><au>Bascuas, Thais</au><au>Rimsky, Geraldine</au><au>Agorio, Caroline Isabel</au><au>Chabalgoity, José Alejandro</au><au>Moreno, María</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TLR7 agonist in combination with</atitle><jtitle>Immunotherapy</jtitle><date>2018-06-01</date><date>2018-03-01</date><risdate>2018</risdate><risdate>2018</risdate><volume>10</volume><issue>8</issue><spage>665</spage><epage>679</epage><pages>665-679</pages><issn>1750-743X</issn><eissn>1750-7448</eissn><abstract>We evaluated a novel approach combining the use of attenuated immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice. B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumoral injection of attenuated serovar Typhimurium LVR01. The combined therapy resulted in retarded tumor growth and prolonged survival. Combination treatment led to an enhancement in the expression of pro-inflammatory cytokines and chemokines in the tumor microenvironment, with a Th1-skewed profile, resulting in a broad antitumor response. The induced immunity was effective in controlling the occurrence of metastasis. LVR01 immunotherapy in combination with imiquimod is a novel approach that could be considered as an effective antimelanoma therapy.</abstract><pub>Future Medicine Ltd</pub><doi>10.2217/imt-2017-0188</doi></addata></record>
fulltext fulltext
identifier ISSN: 1750-743X
ispartof Immunotherapy, 2018-06, Vol.10 (8), p.665-679
issn 1750-743X
1750-7448
language eng
recordid cdi_futurescience_futuremedicine_10_2217_imt_2017_0188
source PubMed Central
subjects experimental model
imiquimod
immunotherapy
melanoma
title TLR7 agonist in combination with
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A54%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-futurescience&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TLR7%20agonist%20in%20combination%20with&rft.jtitle=Immunotherapy&rft.au=Vola,%20Magdalena&rft.date=2018-06-01&rft.volume=10&rft.issue=8&rft.spage=665&rft.epage=679&rft.pages=665-679&rft.issn=1750-743X&rft.eissn=1750-7448&rft_id=info:doi/10.2217/imt-2017-0188&rft_dat=%3Cfuturescience%3E10_2217_imt_2017_0188%3C/futurescience%3E%3Cgrp_id%3Ecdi_FETCH-futurescience_futuremedicine_10_2217_imt_2017_01883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true